Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos has initiated GLPG0259 Phase II clinical study to evaluate the safety and efficacy of this novel drug in rheumatoid arthritis (RA) patients.
Subscribe to our email newsletter
The primary endpoint will be the ACR20 response rate, the standard primary endpoint for RA clinical trials.
Galapagos intends to declare the interim results by the middle of next year and complete the trial by the end of 2011.
Galapagos CEO Onno van de Stolpe said that this trial marks the first time a Galapagos novel target candidate drug is tested in patients.